



Selection criteria

Selection period: 2011-2019


Database extracted in Jan-2026

*Data collected from patient medical files
Quality control processes and yearly updates*

- ≥18 years old
- who received a initial treatment (partial or complete) for ovarian cancer (surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, diagnostic procedure, other specific therapeutic procedure) at one of the participating medical center

13 275 patients

Median age at
primary diagnosis **62** years



Treatments

12 432 patients who received
a **first line of treatment**

9 943 patients
who experienced a **surgery
with resection** in 1L

6 069 patients with **PDS**

5 317 patients with **IDS**


3 601 **Platinum-resistant**

1618 1L PROC; **1 983** 2L+ PROC



1 926 patients who received
a **PARP inhibitor in 2L+**

5 677 patients
who received **bevacizumab**

Histology



Other tumors 6%



Genetic testing

7 318 patients with **HRR panel testing**

1 636 patients with a **HRD**

7 299 patients with **BRCA testing**

1 574 patients with a **germline BRCA mutation**

Follow-up

Median follow-up 109.6 months

According to reverse Kaplan-Meier Method

Minimum estimated follow-up

- 36 months for 11 574 patients
- 60 months for 10 741 patients